Clinical Trial Watch: Localized Prostate Cancer

Localized Prostate Cancer

• Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate CancerSponsor(s): Medical University of South Carolina
Identifier: NCT00099086

• Preoperative Radiation Therapy for High Risk Prostate CancerSponsor(s): Duke University, Virginia Commonwealth University
Identifier: NCT01041326

• A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate CancerSponsor(s): Cedars-Sinai Medical Center, Bristol-Myers Squibb
Identifier: NCT00672009

• Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate CancerSponsor(s): EDAP TMS S.A.
Identifier: NCT00295802

• Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate CancerSponsor(s): University of California, Los Angeles
Identifier: NCT01059513

• Sorafenib in Treating Patients Undergoing Radical Prostatectomy for High-Risk Localized Prostate CancerSponsor(s): Fred Hutchinson Cancer Research Center, National Cancer Institute
Identifier: NCT00466752

• Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate CancerSponsor(s): Oregon Health and Science University, National Cancer Institute
Identifier: NCT00321698

• Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate CancerSponsor(s): Mayo Clinic, National Cancer Institute
Identifier: NCT00714753

• Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate CancerSponsor(s): Memorial Sloan-Kettering Cancer Center, National Cancer Institute
Identifier: NCT00589472

• Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical ProstatectomySponsor(s): University of Washington, sanofi aventis
Identifier: NCT00223665

• Prostate Cancer Symptom Management for Low Literacy MenSponsor(s): Baylor College of Medicine, American Cancer Society, Michael DeBakey Veterans Affairs Medical Center
Identifier: NCT00983710

• Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate CancerSponsor(s): Brown University, Rhode Island Hospital, The Miriam Hospital
Identifier: NCT00828308

• Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate CancerSponsor(s): Beth Israel Medical Center, Bayer
Identifier: NCT00924807